Incannex engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating…
Highlights: Incannex has engaged Fortrea as the contract research organisation (‘CRO’) to manage the IND opening Phase 2/3 clinical trial investigating IHL-42X for treatment of OSA.The Phase 2/3 clinical trial will assess the safety and…